يعرض 1,481 - 1,500 نتائج من 13,123 نتيجة بحث عن '(( significant increase decrease ) OR ( significant ((side decrease) OR (step decrease)) ))*', وقت الاستعلام: 0.66s تنقيح النتائج
  1. 1481
  2. 1482
  3. 1483

    Initial participants by wave*. حسب Yeo Ju Sohn (18536198)

    منشور في 2024
    الموضوعات:
  4. 1484
  5. 1485
  6. 1486
  7. 1487
  8. 1488
  9. 1489
  10. 1490
  11. 1491

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  12. 1492

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  13. 1493

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  14. 1494
  15. 1495
  16. 1496
  17. 1497
  18. 1498
  19. 1499
  20. 1500